Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr791 Activators

Olfr791 belongs to the olfactory receptor family, which is integral to the sense of smell. As a G protein-coupled receptor (GPCR), Olfr791 is involved in detecting specific odorant molecules, triggering a cascade of intracellular signaling events. The function of Olfr791, like many olfactory receptors, involves the binding of odorant molecules, leading to receptor conformational changes. These changes facilitate the coupling with G proteins, initiating intracellular signaling cascades that translate the chemical signal of the odorant into a neuronal response. The detailed ligand specificity and broader physiological roles of Olfr791 are not fully characterized, reflecting the complex nature of the olfactory system and GPCR-mediated signal transduction. The activation mechanisms of Olfr791 are influenced by the cellular milieu and the presence of various signaling molecules. A critical regulator in this context is the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP, a widely recognized second messenger, is involved in numerous cellular processes, including the modulation of GPCR signaling. The production of cAMP is governed by adenylate cyclase, which converts ATP into cAMP in response to various stimuli. The generated cAMP activates protein kinase A (PKA), which then phosphorylates a range of target proteins, including GPCRs. This phosphorylation can modulate the sensitivity and responsiveness of GPCRs to their ligands. Moreover, cAMP can influence other signaling pathways that intersect with GPCR signaling, thereby indirectly modulating GPCR activity, including that of Olfr791.

Phosphodiesterases (PDEs), which catalyze the degradation of cAMP, are pivotal in regulating its intracellular concentration. Inhibiting PDEs can lead to an accumulation of cAMP within the cell, indirectly affecting GPCR signaling, including the pathways associated with Olfr791. Chemicals that inhibit PDEs, thereby increasing cAMP levels, can indirectly modulate Olfr791 activity through alterations in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Additionally, compounds that directly increase cAMP levels, such as activators of adenylate cyclase or β-adrenergic receptor agonists, can also indirectly influence Olfr791 activity. These interactions underscore the complexity of GPCR regulation and highlight the potential of chemical compounds to modulate the activity of these receptors indirectly. In conclusion, the activation of Olfr791 is a multifaceted process that involves complex interactions between various cellular components and signaling molecules. Understanding the intricacies of these interactions and the potential of chemical compounds to modulate GPCR activity offers significant insights into the function of olfactory receptors and their roles in physiological processes.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Isoproterenol Hydrochloride

51-30-9sc-202188
sc-202188A
100 mg
500 mg
$28.00
$38.00
5
(0)

Isoproterenol, a synthetic catecholamine, acts as a β-adrenergic agonist, elevating intracellular cAMP through adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr791 signaling pathways, enhancing receptor activation and signal transduction.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. This elevation may indirectly influence Olfr791 by modulating GPCR signaling pathways, altering receptor dynamics and signaling efficacy.

(−)-Epinephrine

51-43-4sc-205674
sc-205674A
sc-205674B
sc-205674C
sc-205674D
1 g
5 g
10 g
100 g
1 kg
$41.00
$104.00
$201.00
$1774.00
$16500.00
(1)

Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors to increase cAMP via adenylate cyclase. This cAMP surge could indirectly affect Olfr791 activation, potentially enhancing its activity through downstream signaling cascades.

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$77.00
$216.00
18
(1)

Rolipram selectively inhibits phosphodiesterase 4 (PDE4), increasing cAMP levels. Elevated cAMP may enhance Olfr791 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics and downstream signaling.

Cilostamide (OPC 3689)

68550-75-4sc-201180
sc-201180A
5 mg
25 mg
$92.00
$357.00
16
(1)

Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr791 activation by affecting GPCR-mediated signaling pathways, possibly through receptor trafficking or signaling efficiency alterations.

Salbutamol

18559-94-9sc-253527
sc-253527A
25 mg
50 mg
$94.00
$141.00
(1)

Salbutamol, a β2-adrenergic agonist, raises cAMP levels via adenylate cyclase activation. This increase might boost Olfr791 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction.

Theophylline

58-55-9sc-202835
sc-202835A
sc-202835B
5 g
25 g
100 g
$20.00
$32.00
$85.00
6
(0)

Theophylline, a non-selective phosphodiesterase inhibitor, raises cAMP and cGMP levels. Elevated cAMP might stimulate Olfr791 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling.

Dobutamine

34368-04-2sc-507555
100 mg
$295.00
(0)

Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors to increase cAMP. This elevation could modulate Olfr791 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics.

Milrinone

78415-72-2sc-201193
sc-201193A
10 mg
50 mg
$165.00
$697.00
7
(0)

Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr791 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy.